Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment
A Becker, L Crombag, DAM Heideman… - European journal of …, 2011 - Elsevier
BACKGROUND: Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor
(EGFR) are approved as treatment of non-small-cell lung cancer (NSCLC). Despite an …
(EGFR) are approved as treatment of non-small-cell lung cancer (NSCLC). Despite an …
EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case–control …
M Faehling, R Eckert, T Kamp, S Kuom, U Griese… - Lung cancer, 2013 - Elsevier
INTRODUCTION: Some patients with advanced NSCLC show prolonged disease
stabilization on treatment with an EGFR-tyrosine kinase inhibitor (TKI) such as erlotinib. It is …
stabilization on treatment with an EGFR-tyrosine kinase inhibitor (TKI) such as erlotinib. It is …
Randomized phase II trial of erlotinib beyond progression in advanced erlotinib-responsive non-small cell lung cancer
Background. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …
[HTML][HTML] Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a …
S Watanabe, J Tanaka, T Ota, R Kondo, H Tanaka… - BMC cancer, 2011 - Springer
Background Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …
[HTML][HTML] Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer
AS Wong, R Soong, SBK Seah, SW Lim… - Journal of Thoracic …, 2008 - Elsevier
Introduction The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
gefitinib and erlotinib are gaining an increasing role in the management of advanced non …
gefitinib and erlotinib are gaining an increasing role in the management of advanced non …
Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI).
SB Goldberg, GR Oxnard, S Digumarthy, A Muzikansky… - 2012 - ascopubs.org
7524 Background: EGFR-mutant NSCLC has an oncogene-addicted phenotype that confers
sensitivity to EGFR TKIs. Prior data suggests EGFR addiction persists after development of …
sensitivity to EGFR TKIs. Prior data suggests EGFR addiction persists after development of …
Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib …
Purpose: Treatment of patients with oncogene-addicted cancers with tyrosine kinase
inhibitors (TKI) is biologically and clinically different than with cytotoxic chemotherapy. We …
inhibitors (TKI) is biologically and clinically different than with cytotoxic chemotherapy. We …
Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer
A Viswanathan, G Pillot, R Govindan - Lung Cancer, 2005 - lungcancerjournal.info
Epidermal growth factor receptor (EGFR) has been extensively studied as a target in the
treatment of non-small cell lung cancer. Gefitinib (ZD 1839, Iressa) and erlotinib (OSI 774 …
treatment of non-small cell lung cancer. Gefitinib (ZD 1839, Iressa) and erlotinib (OSI 774 …
[HTML][HTML] Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
MK Wong, AI Lo, B Lam, WK Lam, MS Ip… - Cancer chemotherapy and …, 2010 - Springer
Purpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer
(NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR …
(NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR …
[HTML][HTML] Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an …
Y Goto, C Tanai, K Yoh, Y Hosomi, H Sakai, T Kato… - ESMO open, 2017 - Elsevier
Background Some patients with advanced or recurrent, epidermal growth factor receptor
(EGFR) mutation-positive (EGFR M+) non-small-cell lung cancer (NSCLC) continue to …
(EGFR) mutation-positive (EGFR M+) non-small-cell lung cancer (NSCLC) continue to …
相关搜索
- drug holiday retreatment with erlotinib
- drug holiday patients with nsclc
- egfr tki retreatment with erlotinib
- drug holiday egfr tki
- egfr tki patients with nsclc
- egfr tki lung cancer
- egfr tki radiological progression
- gefitinib in patients rechallenge treatment
- tki sensitivity retreatment with erlotinib
- drug holiday tki sensitivity
- tki sensitivity patients with nsclc